Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine
NCT06485752 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL
Last updated 2025-03-11
Summary
Phase 3 Study Comparing Safety and Immune Response of Three Batches of Novavax Flu Vaccine in older adult participants
Conditions
Interventions
- BIOLOGICAL
-
tNIV 1 and Matrix-M Adjuvant
tNIV will be administered as a single 0.5 mL IM injection Day 0
Sponsors & Collaborators
-
Novavax
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 60 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-11-30
- Primary Completion
- 2025-02-04
- Completion
- 2025-02-04
- FDA Drug
- Yes
More Related Trials
-
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
NCT04961541 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine
NCT05519839 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
NCT06602024 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
NCT06097273 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults
NCT06680375 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults
NCT00395174 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults
NCT01561768 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults
NCT01014806 ·Status: COMPLETED ·Phase: PHASE2
-
RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly
NCT01709019 ·Status: COMPLETED ·Phase: PHASE1
-
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above
NCT04841577 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
NCT06864143 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults
NCT03026348 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations
NCT01746082 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age
NCT06694389 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
NCT04583995 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
NCT05415462 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
NCT05585632 ·Status: COMPLETED ·Phase: PHASE1
-
A Study About Modified RNA Vaccines Against Influenza in Healthy Adults
NCT06436703 ·Status: COMPLETED ·Phase: PHASE2
-
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
NCT05827978 ·Status: COMPLETED ·Phase: PHASE3
-
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
NCT06695117 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above
NCT05829356 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older
NCT05624606 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults
NCT06237049 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
NCT06508320 ·Status: COMPLETED ·Phase: PHASE2
-
A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant
NCT02078674 ·Status: COMPLETED ·Phase: PHASE1/PHASE2